360 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Pilgrim Partners Asia Pte Ltd

Pilgrim Partners Asia Pte Ltd acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 360 shares of the company’s stock, valued at approximately $59,000.

Other hedge funds also recently bought and sold shares of the company. Callahan Advisors LLC increased its stake in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. CIBC Asset Management Inc increased its stake in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the period. Pensionfund Sabic lifted its position in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $1,764,000. Finally, Alberta Investment Management Corp increased its stake in Zoetis by 2,050.0% in the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after purchasing an additional 28,700 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 4.9 %

Zoetis stock opened at $151.76 on Friday. The company has a market capitalization of $67.96 billion, a P/E ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. The firm’s fifty day simple moving average is $165.71 and its 200-day simple moving average is $173.58. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $215.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.